Psilera Closes Oversubscribed $8.8M Seed Funding Round to Accelerate Neuroplastogen PSIL-006 Into the Clinic

Psilera Inc., a biopharmaceutical company specializing in neuroplastogens and psychedelic therapies, has successfully closed an oversubscribed $8.8 million Series Seed extension funding round. This funding round, announced on May 28, 2026, was led by a syndicate of institutional and strategic investors. The capital raised will be utilized to advance Psilera's lead clinical asset, PSIL-006, towards its anticipated first-in-human trials scheduled for 2027.

Psilera is focused on developing innovative treatments for neurological conditions, leveraging the therapeutic potential of traditional psychedelic compounds while minimizing associated risks, such as hallucinogenic effects and cardiovascular complications. PSIL-006 represents a first-in-class neuroplastogen, designed to provide safe and effective therapeutic options for patients. The recent funding marks a critical transition for Psilera, moving from a discovery-stage research company to a clinical-stage organization, a shift that is essential for the advancement of its product pipeline.

The funding comes at a time when interest in psychedelic therapies is gaining momentum, driven by increasing recognition of their potential benefits in treating various mental health disorders. The recent U.S. Executive Order aimed at accelerating medical treatments for serious mental illness further underscores the regulatory landscape's evolving support for such therapies. Psilera's strategy aligns with this trend, as the company aims to capitalize on the growing acceptance and demand for innovative mental health solutions.

In addition to the funding, Psilera has achieved several significant milestones that enhance its clinical development capabilities. The appointment of Dr. Magali Haas, a distinguished neuroscience expert, as Chief Medical Officer, and the receipt of a National Institutes of Health (NIH) funding award of up to $2 million for studies related to alcohol use disorder (AUD) underscore the company's commitment to advancing its research agenda. Furthermore, a strategic licensing agreement with atai Life Sciences for its DMT patent portfolio positions Psilera favorably within the competitive landscape.

The successful completion of this funding round not only strengthens Psilera's financial position but also highlights the increasing investor confidence in the biopharmaceutical sector, particularly in the realm of psychedelic therapies. As the market for innovative mental health treatments continues to expand, Psilera's advancements in neuroplastogen development could play a pivotal role in shaping the future of therapeutic options for neurological conditions. The broader implications of this funding round may signal a shift in how investors approach opportunities within the biopharmaceutical industry, particularly those that focus on breakthrough therapies for mental health challenges.